J Korean Neurol Assoc.  2019 May;37(2):171-173. 10.17340/jkna.2019.2.9.

Improved Bulbar Function in Amyotrophic Lateral Sclerosis after Nuedexta (Dextromethorphan and Quinidine) Treatment

Affiliations
  • 1Department of Neurology, Kyungpook National University Chilgok Hospital, Daegu, Korea. jinforeva@gmail.com
  • 2Department of Neurology, Dongguk University College of Medicine, Gyeongju, Korea.
  • 3Department of Neurology, School of Medicine, Kyungpook National University, Daegu, Korea.

Abstract

Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients.

Keyword

Dextromethorphan; Quinidine; Amyotrophic lateral sclerosis

MeSH Terms

Amyotrophic Lateral Sclerosis*
Deglutition
Dextromethorphan
Humans
Quinidine
United States Food and Drug Administration
Dextromethorphan
Quinidine
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error